Abstract
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a recognized treatment option for patients with relapsed diffuse large B-cell lymphoma. We have analysed 51 patients who underwent ASCT after LACE (lomustine (CCNU), cytarabine (Ara-C), cyclophosphamide, etoposide) conditioning for relapsed (n = 34, 67%) or primary refractory (n = 17, 33%) diffuse large B-cell lymphoma. With a median follow-up of 60 months (range 2-216) the probabilities of overall survival (OS) and progression-free survival (PFS) at 5 years were 47 and 42%, respectively. The cumulative treatment-related mortality was 10% (n = 5). Probabilities for OS and PFS at 5 years were 56 and 50% for patients with chemosensitive and 29 and 27% for patients with chemorefractory disease. In multivariate analysis abnormal pre-ASCT levels of C-reactive protein (>5 mg/L) were identified as a risk factor for worse OS, whereas abnormal pre-ASCT levels of C-reactive protein and chemoresistance predicted inferior PFS. LACE followed by ASCT is an effective treatment for approximately half of patients with chemosensitive relapsed diffuse large B-cell lymphoma, and a proportion of chemorefractory patients also benefit.
References
Apr 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F B PetersenR Storb
Jun 11, 1987·The New England Journal of Medicine·T PhilipM Flesh
Dec 7, 1995·The New England Journal of Medicine·T PhilipJ L Harousseau
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W MillsA H Goldstone
Jun 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C WheelerJ P Eder
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J StiffR I Fisher
Jul 29, 1998·Cancer Investigation·B Shank
Sep 18, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J R AndersonD D Weisenburger
Dec 30, 1998·Leukemia & Lymphoma·E LegouffeT Commes
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseUNKNOWN Autologous Blood and Marrow Transplant Registry Lymphoma Working Committee
Apr 21, 2001·Bone Marrow Transplantation·A SalarUNKNOWN GEL/TAMO Spanish Cooperative Group
Apr 25, 2001·Bone Marrow Transplantation·A K GopalO W Press
Oct 11, 2001·Bone Marrow Transplantation·F Gutierrez-DelgadoW I Bensinger
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Dec 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M D CaballeroE Conde
Jan 18, 2006·Bone Marrow Transplantation·E JantunenT Nousiainen
Nov 23, 2006·Bone Marrow Transplantation·J B PerzE J Kanfer
Jul 20, 2007·European Journal of Haematology·Yair HerishanuElizabeth Naparstek
Oct 8, 2008·Haematologica·Esa JantunenUNKNOWN EBMT Lymphoma Working Party
Oct 23, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Andrew S ArtzKoen van Besien
Mar 23, 2010·Blood·Jirí PavlůRichard M Szydlo
Citations
Feb 8, 2013·Leukemia & Lymphoma·Holger W AunerAmin Rahemtulla
Jan 6, 2016·International Journal of Hematology·Navin KhattryTapan Saikia
Jul 24, 2018·Leukemia & Lymphoma·Wenqiong QinQiusong Chen
Sep 11, 2018·Journal of Cancer Research and Therapeutics·Alok GuptaNavin Khattry
Mar 6, 2019·Nature·Ravindra K GuptaEduardo Olavarria
Sep 26, 2019·Frontiers in Oncology·Andrei ColitaAlina Tanase